Hierarchical Diagnosis for Adult Diffuse Glioma Based on Deep Learning

Nanjing University

Status: Enrolling

Conditions: Oligodendroglioma; Glioblastoma Multiforme; Astrocytoma

Treatments: Diagnostic Test: Pathology examination; Diagnostic Test: multi-parametric magnetic resonance imaging scan

Study type: Observational

Funder types: Other

Identifiers

NCT05624736

2022-LCYJ-MS-25

Details and patient eligibility

About

This is a restrospective study to establish a deep learning model based on multi-parametric magnetic resonance imaging scans to predict Grade, histopathologic type and genotype of adult diffuse Glioma.

Full description

Glioma is a common kind of tumor in central nervous system. The pre-operative prediction of grade, histopathologic type and genotype is important for treatment and management of Adult diffuse Glioma patients. Right now, most of the diagnostic prediction models on glioma are based on 2016 WHO central nervous system tumor guideline. The goal of this study is to establish a new deep learning model to predict Grade, histopathologic type and genotype of adult diffuse Glioma. We will recruit 500 patients with pathologically confirmed diagnosis of Glioblastoma, Astrocytoma and Oligodendroglioma who received neurologic surgery in our center. Each subject underwent pre-operative multi-parametric magnetic resonance imaging scans including T1WI, T2WI, T1CE, FLAIR and DWI. Pathologic diagnosis of each patient are available in pathology department. A deep learning based hierarchical diagnosis

Enrollment: 500 estimated patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients undergoing surgery in Nanjing DrumTower Hospital between 2010.01 and 2022.05 with post-surgery pathological diagnosis of WHO Grade II to IV Adult Diffuse Glioma.
2. Available pre-surgery T1WI, T2WI, T1CE, FLARI and DWI MR sequences
3. No pre-surgery anti-tumor therapy

Exclusion criteria

1. Poor image quality
2. Failed image preprocessing
3. Unavailable pathology data

Trial design

500 participants in 3 patient groups

Glioblastoma Group

Description:

Patients with the diagnosis of Glioblastoma based on 2021 WHO central nervous system tumor guideline.

Treatment:

Diagnostic Test: multi-parametric magnetic resonance imaging scan

Diagnostic Test: Pathology examination

Astrocytoma Group

Description:

Patients with the diagnosis of Astrocytoma based on 2021 WHO central nervous system tumor guideline.

Treatment:

Diagnostic Test: multi-parametric magnetic resonance imaging scan

Diagnostic Test: Pathology examination

Oligodendroglioma Group

Description:

Patients with the diagnosis of Oligodengroglioma based on 2021 WHO central nervous system tumor guideline.

Treatment:

Diagnostic Test: multi-parametric magnetic resonance imaging scan

Diagnostic Test: Pathology examination